The use of hormone and targeted therapy is dependent on the female sex hormone receptor (HR) (estrogen receptors [ER] and progesterone receptors [PR]) and human epidermal growth factor receptor 2 (HER2) status in addition to the histologic type of breast cancer, grade, lymph nodes, and distant metastatic organ involvement [9, 10]. This evidence concerns the gene ESR1 and breast carcinoma.